Cayman RRx-001

RRx-001 is an anticancer agent. It inhibits growth in a panel of 12 cancer cell lines (IC₅₀s =1.8-6 μM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 μM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mm) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions. RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.

WARNING This product is not for human or veterinary use.